Harry J. Leonhardt
2019 - Halozyme Therapeutics
Compensation breakdown
| Non-Equity Incentive Plan | $217,152 |
|---|---|
| Option Awards | $625,007 |
| Salary | $464,000 |
| Stock Awards | $625,008 |
| Other | $16,536 |
| Total | $1,947,703 |
Leonhardt received $625K in stock awards, accounting for 32% of the total pay in 2019.
Leonhardt also received $217.2K in non-equity incentive plan, $625K in option awards, $464K in salary and $16.5K in other compensation.
Rankings
In 2019, Harry J. Leonhardt's compensation ranked 6,076th out of 13,971 executives tracked by ExecPay. In other words, Leonhardt earned more than 56.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,076 out of 13,971 | 57th |
Division Manufacturing | 2,280 out of 5,701 | 60th |
Major group Chemicals And Allied Products | 824 out of 2,200 | 63rd |
Industry group Drugs | 696 out of 1,886 | 63rd |
Industry Biological Products, Except Diagnostic Substances | 165 out of 389 | 58th |
Pay ratio
| Harry J. Leonhardt's Pay | $1,947,703 |
|---|---|
| Median Employee's Pay | $238,096 |
| Pay Ratio | 8to 1 |
In 2019, the annual total compensation of Harry J. Leonhardt was $1,947,703.
The annual total compensation of the median employee at Halozyme Therapeutics was $238,096.
The ratio of Harry J. Leonhardt's pay to the pay of median employee was therefore 8 to one.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2019.
2019
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
2019
Alison Armour
Halozyme Therapeutics
Former Senior Vice President, Head of Research & Development
2019
Laurie Stelzer
Halozyme Therapeutics
Chief Financial Officer
2019
Benjamin Hickey
Halozyme Therapeutics
Former Senior Vice President, Chief Commercial Officer
News
April 26, 2023
April 27, 2022
March 20, 2020
March 22, 2019